Literature DB >> 26388229

Tackling reproducibility in academic preclinical drug discovery.

Stephen V Frye1, Michelle R Arkin2, Cheryl H Arrowsmith3, P Jeffrey Conn4, Marcie A Glicksman5, Emily A Hull-Ryde1, Barbara S Slusher6.   

Abstract

The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.

Mesh：

Year:  2015        PMID： 26388229     DOI： 10.1038/nrd4737

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  5 in total

1.  Believe it or not: how much can we rely on published data on potential drug targets?

Authors:  Florian Prinz; Thomas Schlange; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

2.  Drug discoverers chart path to tackling data irreproducibility.

Authors:  Elie Dolgin
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694

3.  Chemistry: Chemical con artists foil drug discovery.

Authors:  Jonathan Baell; Michael A Walters
Journal:  Nature       Date:  2014-09-25       Impact factor: 49.962

4.  The promise and peril of chemical probes.

Authors:  Cheryl H Arrowsmith; James E Audia; Christopher Austin; Jonathan Baell; Jonathan Bennett; Julian Blagg; Chas Bountra; Paul E Brennan; Peter J Brown; Mark E Bunnage; Carolyn Buser-Doepner; Robert M Campbell; Adrian J Carter; Philip Cohen; Robert A Copeland; Ben Cravatt; Jayme L Dahlin; Dashyant Dhanak; Aled M Edwards; Mathias Frederiksen; Stephen V Frye; Nathanael Gray; Charles E Grimshaw; David Hepworth; Trevor Howe; Kilian V M Huber; Jian Jin; Stefan Knapp; Joanne D Kotz; Ryan G Kruger; Derek Lowe; Mary M Mader; Brian Marsden; Anke Mueller-Fahrnow; Susanne Müller; Ronan C O'Hagan; John P Overington; Dafydd R Owen; Saul H Rosenberg; Bryan Roth; Brian Roth; Ruth Ross; Matthieu Schapira; Stuart L Schreiber; Brian Shoichet; Michael Sundström; Giulio Superti-Furga; Jack Taunton; Leticia Toledo-Sherman; Chris Walpole; Michael A Walters; Timothy M Willson; Paul Workman; Robert N Young; William J Zuercher
Journal:  Nat Chem Biol       Date:  2015-08       Impact factor: 15.040

5.  An open investigation of the reproducibility of cancer biology research.

Authors:  Timothy M Errington; Elizabeth Iorns; William Gunn; Fraser Elisabeth Tan; Joelle Lomax; Brian A Nosek
Journal:  Elife       Date:  2014-12-10       Impact factor: 8.140
  5 in total
  21 in total

1.  Challenges with risk mitigation in academic drug discovery: finding the best solution.

Authors:  Anuradha Roy
Journal:  Expert Opin Drug Discov       Date:  2018-12-04       Impact factor: 6.098

Review 2.  Personalized Therapy of Hypertension: the Past and the Future.

Authors:  Paolo Manunta; Mara Ferrandi; Daniele Cusi; Patrizia Ferrari; Jan Staessen; Giuseppe Bianchi
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 3.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

4.  Common pitfalls in preclinical cancer target validation.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2017-05-19       Impact factor: 60.716

Review 5.  Non-kinase targets of protein kinase inhibitors.

Authors:  Lenka Munoz
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

Review 6.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 7.  Mechanistic enzymology in drug discovery: a fresh perspective.

Authors:  Geoffrey A Holdgate; Thomas D Meek; Rachel L Grimley
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

8.  Furoxans (Oxadiazole-4 N-oxides) with Attenuated Reactivity are Neuroprotective, Cross the Blood Brain Barrier, and Improve Passive Avoidance Memory.

Authors:  Austin Horton; Kevin Nash; Ethel Tackie-Yarboi; Alexander Kostrevski; Adam Novak; Aparna Raghavan; Jatin Tulsulkar; Qasim Alhadidi; Nathan Wamer; Bryn Langenderfer; Kalee Royster; Maxwell Ducharme; Katelyn Hagood; Megan Post; Zahoor A Shah; Isaac T Schiefer
Journal:  J Med Chem       Date:  2018-05-07       Impact factor: 7.446

9.  Target class drug discovery.

Authors:  Kimberly D Barnash; Lindsey I James; Stephen V Frye
Journal:  Nat Chem Biol       Date:  2017-09-19       Impact factor: 15.040

10.  Reproducibility of histopathological findings in experimental pathology of the mouse: a sorry tail.

Authors:  Jerrold M Ward; Paul N Schofield; John P Sundberg
Journal:  Lab Anim (NY)       Date:  2017-03-22       Impact factor: 12.625
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.